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Background: Clusterin is known to be expressed in many human neoplasms, and is believed to participate in the
regeneration, migration, and anti-apoptosis of tumor cells. However, few reports have addressed the relationship
between the manifestation of clusterin and clinicopathologic parameters in pancreas cancer patients. In the present
study, the authors investigated the expression of clusterin and its clinical significance in pancreatic adenocarcinoma.
Methods: Immunohistochemical staining was performed for clusterin in tumor tissues obtained from patients who
received pancreatic resection with radical intent, and the associations of clusterin expression with various
clinicopathologic parameters were analyzed in addition to the relation between its expression and survival.
Results: Immunoreactivity for clusterin was observed in 17 of the 52 (33%) pancreatic adenocarcinomas examined.
In addition, clusterin positivity was found to be associated with preoperative serum carcinoembryonic antigen level,
perineural invasion, and, most strongly, lymph node metastasis. The survival analysis identified tumor differentiation
and lymph node metastasis as the only significant prognostic factors.
Conclusion: Although not an independent prognostic factor, clusterin immunoreactivity can be used in
conjunction with lymph node metastasis to predict survival in cases of pancreatic adenocarcinoma.
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Pancreatic cancer is a fatal disease with an annual inci-
dence that approaches its mortality rate [1,2], and the 5-
year survival rate is about 5% [3]. Pancreatic adenocar-
cinoma accounts for most pancreatic cancers, and lymph
node metastasis is one of the most significant prognostic
factors in pancreatic adenocarcinoma patients. However,
the extent of lymph node dissection is highly dependent
on the operator and the number of dissected nodes can
be small, especially when malignancy is not suspected
preoperatively. A new biological predictive marker is
therefore needed to supplement lymph node status,
which can also be used to evaluate the efficacy of adju-
vant treatments.
Clusterin is ubiquitously expressed in al most all mam-
malian tissues and has been found in all human body* Correspondence: 196087@inha.ac.kr
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reproduction in any medium, provided the orfluids analyzed [4]. Furthermore, clusterin is also known
to be overexpressed in various cancer tissues, including
pancreatic cancer [5]. However, the role played by clus-
terin in pancreatic cancer cells is still unclear, and its
clinical significance has yet to be determined. There are
two isoforms of clusterin identified, the secretory and
the nuclear isoforms [6]. In the present study, we inves-
tigated relations between expression of the secretory iso-
form of clusterin and clinicopathologic parameters to
assess its potential value as a prognostic indicator in
pancreatic adenocarcinoma.Methods
Pancreatic cancer samples
Pathologically proven pancreatic adenocarcinoma tissue
samples were obtained from 52 consecutive patients
who underwent surgical resection with radical intent in
Inha University Hospital from July 1997 to June 2008.
All samples were collected using protocols approved byThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sents were obtained from all the patients.
Immunohistochemical analysis
Imunohistochemical staining was performed as described
previously [7]. All surgical specimens were fixed in 10%
formalin, embedded in paraffin, and consecutively sec-
tioned at 5 μm. Most representative sections from eachTable 1 Correlations between clusterin expression and clinico
in pancreatic adenocarcinoma
Parameter Number of cases (%) Clusterin ex
Clusterin-po
Overall 52 (100.0) 17 (32.7)
Age
≥65 years 35 (67.3) 11 (31.4)
< 65 years 17 (32.7) 6 (35.3)
Sex
Male 37 (71.2) 13 (35.1)
Female 15 (28.8) 4 (26.7)
Tumor size
≤2 cm 9 (17.3) 1 (11.1)
> 2 cm 43 (82.7) 16 (37.2)
Location
Head 44 (84.6) 13 (29.5)
Body/tail 8 (15.4) 4 (50.0)
Pathologic grade
Well/moderately differentiated 42 (80.8) 13 (31.0)
Poorly differentiated/anaplastic 10 (19.2) 4 (40.0)
Perineural invasion
No 8 (15.4) 0 (0.0)
Yes 44 (84.6) 17 (32.7)
Lymphovascular invasion
No 15 (28.8) 3 (20.0)
Yes 37 (71.2) 14 (37.8)
Preoperative CEA (ng/ml)
≤5 32 (69.6) 8 (25.0)
> 5 14 (30.4) 8 (57.1)
Preoperative CA19-9 (U/ml)
≤37 15 (33.3) 5 (33.3)
> 37 30 (66.7) 10 (33.3)
Lymph node metastasis
No 16 (31.4) 1 (6.3)
Yes 35 (68.6) 16 (45.7)
Clusterin expression
Negative 35 (67.3) –
Positive 17 (32.7) –
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.case were dewaxed in xylene and treated with 0.5% hydro-
gen peroxide in absolute methanol for 30 minutes to block
endogenous peroxidase activity. The sections were then
washed in PBS and blocked with normal horse serum for
30 minutes at room temperature. Each tissue section was
incubated with goat anti-clusterin antibody (1:800; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight
at 4°C, washed in PBS, and incubated with biotinylatedpathologic parameters and univariate analysis of survival
pression Survival analysis
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tories, Burlingame, CA, USA) as secondary antibody for 1
hour at room temperature. Sections were then developed
using diaminobenzidine tetrahydrochloride solution
(Sigma-Aldrich Corporation, St Louis, MO, USA) and
counterstained with hematoxylin. Islet cells were used as
internal positive controls. Any case showing focally or dif-
fusely positive tumor cell cytoplasm was defined as
clusterin-positive.Figure 1 Clusterin expression in pancreatic adenocarcinoma.
(A) Positive immunohistochemical staining for clusterin in the
cytoplasm of ductal cancer cells near the basement membrane
(arrows, ×400). (B) A clusterin-negative specimen (×200).Clinicopathologic data
Medical records were reviewed retrospectively, and data
were collected from a medical database. Survival data
were extracted from the Korean MicroData Service Sys-
tem (Statistics Korea, Daejeon, Republic of Korea).Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 12.0 (SPSS, Chicago, IL, USA). The chi-
square test was used to examine the nature of the correl-
ation between clusterin expression and clinicopathologic
parameters. Survival rates were determined using the
Kaplan–Meier method and survival differences were
analyzed using the log-rank test. Cox regression was
used to identify prognostic factors by multivariate ana-
lysis. P <0.05 was considered statistically significant.Results
Demographic data and surgical results
There were 37 male and 15 female patients; a male to fe-
male ratio of 2.5:1. The median age was 68 years (range,
44 to 87 years). Tumors were located in the head of the
pancreas in 44 cases and in the body and/or tail in eight
cases (Table 1). All patients with a tumor in the head of
the pancreas were managed by pancreaticoduodenect-
omy with or without gastric pylorus preservation, and
the other eight patients were managed by distal pancrea-
tectomy with splenectomy. One patient with a tumor in-
volving the whole pancreas was managed using a
combined procedure; the tumor was classified as a head
lesion for the statistical analyses. Five patients suc-
cumbed to death within 30 days of surgery; an operative
mortality of 9.6%.Figure 2 Overall survival curve for the 52 study subjects.Expression of clusterin in adenocarcinoma tissues
Clusterin was expressed in 17 of the 52 (32.7%) pancre-
atic adenocarcinoma samples. Clusterin was expressed
in the cytoplasm of cancer cells in clusterin-positive can-
cers, (Figure 1a), and was expressed in normal islets but
not in adenocarcinoma cells in clusterin-negative can-
cers (Figure 1b).Clusterin expression and clinicopathologic characteristics
Relations between clinicopathologic parameters and
clusterin expression were investigated. Clusterin expres-
sion was found to be associated significantly with lymph
node metastasis (P= 0.006), perineural invasion
(P= 0.042) and elevated preoperative serum carcinoem-
bryonic antigen level (P= 0.048), respectively (Table 1).Survival analysis
Overall median and 5-year survivals were 14.9 months
and 16.6%, respectively (Figure 2). The results of univari-
ate analysis conducted to identify factors associated with
survival are shown in Table 1. Age (P=0.029), pathologic
grade (P=0.010), and lymph node metastasis (P=0.002)
(Figure 3) were found to be significant prognostic factors.
Clusterin manifestation was not found to be a significant
prognostic indicator (P=0.312; Figure 4), and lymphovas-
cular invasion was only marginally significant (P=0.055).
Factors with P <0.1 and clusterin status were entered into
the Cox regression multivariate analysis (Table 2). This
Figure 3 Kaplan–Meier survival curves for patients with or
without lymph node metastasis.
Table 2 Multivariate analysis of survival factors
Factor Hazard
ratio
95% confidence interval P
valueLower Upper
Age 1.020 0.973 1.068 0.416
Size 1.728 0.559 5.337 0.342
Pathologic grade 3.462 1.251 9.579 0.017
Lymphovascular invasion 1.144 0.490 2.671 0.756
Lymph node metastasis 4.410 1.587 12.256 0.004
Clusterin expression 0.650 0.283 1.494 0.310
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metastasis were significant prognostic factors.
Discussion
Despite recent diagnostic and management advances,
pancreatic cancer remains a highly lethal disease
[1,2,8,9]. The ability to predict prognosis provides an im-
portant means of determining management protocols
and follow-up schedules. Of the many clinicopathologic
parameters studied, lymph node metastasis has been
most consistently associated with prognosis in pancre-
atic cancer [8,10-12]. Regarding biochemical markers of
prognosis, virtually all potential molecules have beenFigure 4 Kaplan–Meier survival curves by clusterin expressional
status.tested. Recently, in an extensive review of the literature,
Tonini and colleagues concluded that p16, matrix
metalloproteinase-7, and vascular endothelial growth
factor are probably useful indicators of prognosis [13].
Clusterin is a glycoprotein produced by a wide range
of tissues and is present in most body fluids. In its
secretory form, clusterin is believed to be involved in
many physiologic processes, including apoptosis, mor-
phologic transformation, and cell aggregation [6,14]. The
clinical implications of clusterin expression in malignant
diseases are controversial, and its contributions at the
molecular level remain unclear. Clusterin overexpression
has been reported to be marginally related to early re-
currence and shorter survival in breast cancer, especially
in early stage disease [15,16], and has been shown to in-
crease resistance to anti-estrogen hormonal therapy
[17,18]. These results appear to be due to the association
between clusterin expression in breast cancer tissues
and lymph node metastasis and negativity for hormonal
receptors [19,20]. Similarly, clusterin expression in pros-
tate cancer has been correlated with the Gleason tumor
grade [21], and is believed to compromise survival by
inhibiting apoptosis after hormonal ablation therapy
[22]. In a recent study, the possibility that clusterin ex-
pression may confer gemcitabine resistance in pancreatic
cancer was suggested [23]. In ovarian carcinoma, clus-
terin overexpression has been shown to be correlated
with tumor aggressiveness and/or to be a prognostic fac-
tor [24-26]. The results of the present study support the
association of clusterin expression with lymph node me-
tastasis and perineural invasion, and thus with aggressive
tumor behavior of pancreatic adenocarcinoma. These
findings are consistent with those of other studies per-
formed on gastrointestinal adenocarcinomas, in which
cytoplasmic clusterin expression was found to be asso-
ciated with lymph node metastasis and significantly
shorter survival in advanced gastric cancer [27], and
colorectal cancer [28,29]. The exact mechanism of clus-
terin overexpression in enhancing cancer metastasis is
still unclear. One of the plausible explanations is that
clusterin may confer an anti-apoptotic effect on tumor
cells once they are detached from the original site, and
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in the metastatic process [30].
On the other hand, in an in vitro study of nonsmall-
cell lung cancer cell lines, clusterin overexpression was
found to reduce chemosensitivity but indicated a favor-
able prognosis due to the inhibition of tumor cell migra-
tion [31]. Together with the finding that cytoplasmic
clusterin expression is associated with chemoresistance
[32], it is presumed that clusterin is basically cytoprotec-
tive and favorably affects prognosis in early stage lung
cancer but compromises prognosis during late stage dis-
ease by conferring resistance to adjuvant radiotherapy
and chemotherapy [33]. These seemingly disparate
results may be due to a lack of knowledge regarding the
causal relationship between clusterin expression and
tumor cell apoptosis, which can affect patient survival.
Xie and colleagues recently reported associations be-
tween clusterin expression and various pancreatic patholo-
gies including pancreas adenocarcinoma, and concluded
that clusterin positivity is related to improved survival, at
least by univariate analysis [5]. Their results contradict
those of the present study with respect to the direction of
the prognostic influence of clusterin expression. This dis-
agreement may have been caused by the small number of
cases involved in both studies and a shorter follow-up
period in the former study, because in the present study
the survival difference between clusterin-positive and
clusterin-negative patients became apparent in survivors
who had lived longer than 20 months, although the differ-
ence could not reach statistical significance.
To date, clusterin has not been found to be an inde-
pendent prognostic factor for pancreatic adenocarcin-
oma. However, the results of the present study indicate
that clusterin expression is strongly associated with
lymph node metastasis, which is one of the most potent
prognostic indicators. The impact of clusterin expression
on survival can be too weak to be an independent prog-
nostic factor, and further studies with a larger case vol-
ume may reveal the statistical significance. While
extended lymphadenectomy did not show additional sur-
vival benefit [10], regional lymph node dissection still
has a role in predicting the patient’s prognosis [11].
There are also cases in which pancreas adenocarcinoma
was an incidental finding [34], and the extent of lymph
node dissection can be quite varied depending on the
operator. Considering these circumstances, clusterin ex-
pression may provide an adjunctive means, with regard
to the nodal status, in predicting survival, especially
when the presence of malignancy is not suspected pre-
operatively. One of our patients had an occult cancer of
the pancreatic head and underwent pancreaticoduode-
nectomy without lymph node dissection. In this case,
the resected specimen was clusterin-negative, and the
patient survived 57 months after surgery to succumb tononsmall-cell lung cancer. The last abdominal computed
tomography image in this case showed no evidence
of pancreatic cancer recurrence at 47 months after
pancreaticoduodenectomy.
Conclusions
Clusterin expression was not found to be an independent
prognostic factor for pancreatic adenocarcinoma, although
clusterin-negative patients tended to live longer. A further
study on a larger patient population is needed to re-
examine the prognostic value of clusterin expression and
to identify the underlying mechanisms responsible. Never-
theless, the strong association between clusterin expres-
sion and lymph node metastasis suggests that clusterin
can be used as an adjunct to lymph node positivity to pre-
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